Roche oncology chief sees big impact of sugar tech
Three years after plunking down $180 million to buy GlycArt, Roche says the sugar-related technology it acquired in the deal is demonstrating striking effectiveness enhancing experimental cancer therapies. The glycol-engineering tech changes the structure of sugars that coat antibodies, improving new therapies that prod the human immune system to attack cancer cells. Roche's chief of oncology drug development, David Heimbrook, noted that investigators saw the technology at work in mice studies of R7159, which has now entered the clinic.
"The important outcome was that we saw almost complete inhibition of tumor growth," Heimbrook told reporters in New York.
- check out the report from Forbes
Related Articles:
Roche to acquire Swiss antibody-specialist GlycArt
Roche to boost R&D spend, reorganize research
Be the first to comment
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
